Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions

Cirrhotic cardiomyopathy (CCM) is an underdiagnosed cardiac complication of end-stage liver cirrhosis without specific targeted therapies. Gut dysbiosis is hypothesized to act as a modifiable upstream regulator along the gut-liver-heart axis. It may contribute to myocardial remodeling through metabolic, inflammatory, autoimmune, and autonomic pathways, although causal evidence specific to CCM remains insufficient. This narrative review summarizes four proposed pathogenic axes linking intestinal dysbiosis to CCM: (1) bioactive microbial metabolites, including trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids (BAs); (2) systemic immune-inflammatory activation triggered by pathogen-associated molecular patterns (PAMPs); (3) bacterial translocation-related autoimmunity; and (4) autonomic nervous system dysregulation along the gut-brain-heart axis. We stratified these pathways into standardized evidence tiers to distinguish preclinical cardiovascular data, cross-sectional human associations, and unvalidated hypotheses. We further highlight the bidirectional vicious cycle among portal hypertension, gut dysbiosis, and CCM, the lack of CCM-specific randomized controlled trials with cardiac endpoints, and the lack of validated personalized nutritional regimens. The 2019 Cirrhotic Cardiomyopathy Consortium (CCC) established two resting-echocardiography formal diagnostic domains for definitive CCM. The older 2005 Montreal framework combined qualitative systolic and diastolic abnormalities with supportive electrophysiological features, including QTc prolongation; QTc was supportive rather than a primary diagnostic criterion. According to CCC cutoffs: (1) resting systolic dysfunction (LVEF ≤50% or absolute global longitudinal strain (GLS) < 18%); and (2) advanced diastolic dysfunction (at least 3 of 4: septal e′ < 7 cm/s, E/e′ ≥ 15, LAVI >34 mL/m 2 , and TR velocity >2.8 m/s). Blunted stress-induced contractile reserve and isolated QTc prolongation are auxiliary risk markers, not formal diagnostic criteria. Gut microbial metabolites may be evaluated only as complementary research biomarkers and cannot replace standardized cardiac diagnosis. Nutritional interventions targeting gut homeostasis remain experimental hypotheses requiring CCM-specific validation. Finally, we distinguish CCM from metabolic dysfunction-associated steatotic liver disease (MASLD)-associated heart failure with preserved ejection fraction (HFpEF), a distinct syndrome that shares metabolic, inflammatory, and microbiota-derived mechanisms but differs in hemodynamic context, diagnostic criteria, and therapeutic evidence.

Authors

Institutions

Publication Details

Journal
Frontiers in Nutrition
Published
2026-11-18
DOI
https://doi.org/10.3389/fnut.2026.1847556
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions

Ping Yan, Yongqiang Xiong, Cunliang Deng, Changfeng Sun et al.
Frontiers in Nutrition
Gut microbiota and health
article

Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions

Ping Yan, Yongqiang Xiong, Cunliang Deng, Changfeng Sun, Xiaoli Tian
article en

Abstract

Cirrhotic cardiomyopathy (CCM) is an underdiagnosed cardiac complication of end-stage liver cirrhosis without specific targeted therapies. Gut dysbiosis is hypothesized to act as a modifiable upstream regulator along the gut-liver-heart axis. It may contribute to myocardial remodeling through metabolic, inflammatory, autoimmune, and autonomic pathways, although causal evidence specific to CCM remains insufficient. This narrative review summarizes four proposed pathogenic axes linking intestinal dysbiosis to CCM: (1) bioactive microbial metabolites, including trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids (BAs); (2) systemic immune-inflammatory activation triggered by pathogen-associated molecular patterns (PAMPs); (3) bacterial translocation-related autoimmunity; and (4) autonomic nervous system dysregulation along the gut-brain-heart axis. We stratified these pathways into standardized evidence tiers to distinguish preclinical cardiovascular data, cross-sectional human associations, and unvalidated hypotheses. We further highlight the bidirectional vicious cycle among portal hypertension, gut dysbiosis, and CCM, the lack of CCM-specific randomized controlled trials with cardiac endpoints, and the lack of validated personalized nutritional regimens. The 2019 Cirrhotic Cardiomyopathy Consortium (CCC) established two resting-echocardiography formal diagnostic domains for definitive CCM. The older 2005 Montreal framework combined qualitative systolic and diastolic abnormalities with supportive electrophysiological features, including QTc prolongation; QTc was supportive rather than a primary diagnostic criterion. According to CCC cutoffs: (1) resting systolic dysfunction (LVEF ≤50% or absolute global longitudinal strain (GLS) < 18%); and (2) advanced diastolic dysfunction (at least 3 of 4: septal e′ < 7 cm/s, E/e′ ≥ 15, LAVI >34 mL/m 2 , and TR velocity >2.8 m/s). Blunted stress-induced contractile reserve and isolated QTc prolongation are auxiliary risk markers, not formal diagnostic criteria. Gut microbial metabolites may be evaluated only as complementary research biomarkers and cannot replace standardized cardiac diagnosis. Nutritional interventions targeting gut homeostasis remain experimental hypotheses requiring CCM-specific validation. Finally, we distinguish CCM from metabolic dysfunction-associated steatotic liver disease (MASLD)-associated heart failure with preserved ejection fraction (HFpEF), a distinct syndrome that shares metabolic, inflammatory, and microbiota-derived mechanisms but differs in hemodynamic context, diagnostic criteria, and therapeutic evidence.

Frontiers in NutritionVol. 13
Southwest Medical University (CN), Affiliated Hospital of Southwest Medical University (CN)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon